menu

Promising results for APOC3 ASO in familial chylomicronemia syndrome

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Promising results for APOC3 ASO in familial chylomicronemia syndrome

Erik Stroes at the ACC24
Restart
Resume
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    ACC.24 - Results of the Balance trial showed that the APOC3 ASO olezarsen reduces triglycerides in patients with familial chylomicronemia syndrome (FCS). The data of the secondary outcome of new-onset pancreatitis were quite astonishing, according to Erik Stroes.

  • Educational information

    This video was recorded in response to a presentation at the Congress of the American College of Cardiology (ACC) 2024.

  • Faculty

    Erik Stroes, MD, PhD is professor of Vascular Medicine at Amsterdam University Medical Center in Amsterdam, The Netherlands.

  • Disclaimer

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    ACC.24 - Results of the Balance trial showed that the APOC3 ASO olezarsen reduces triglycerides in patients with familial chylomicronemia syndrome (FCS). The data of the secondary outcome of new-onset pancreatitis were quite astonishing, according to Erik Stroes.

  • Educational information

    This video was recorded in response to a presentation at the Congress of the American College of Cardiology (ACC) 2024.

  • Faculty

    Erik Stroes, MD, PhD is professor of Vascular Medicine at Amsterdam University Medical Center in Amsterdam, The Netherlands.

  • Disclaimer

Facebook Comments

Schedule24 May 2024